{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T19:20:23Z","timestamp":1777663223667,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016945","name":"Sidney Kimmel Center for Prostate and Urologic Cancers","doi-asserted-by":"publisher","award":["R37CA276946"],"award-info":[{"award-number":["R37CA276946"]}],"id":[{"id":"10.13039\/100016945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016945","name":"Sidney Kimmel Center for Prostate and Urologic Cancers","doi-asserted-by":"publisher","award":["P50 CA221745"],"award-info":[{"award-number":["P50 CA221745"]}],"id":[{"id":"10.13039\/100016945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017050","name":"Cycle for Survival","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009779","name":"Bladder Cancer Advocacy Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.urolonc.2025.04.006","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T07:13:16Z","timestamp":1748070796000},"page":"520.e19-520.e28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Re-analysis of intravesical gemcitabine in the era of Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive non\u2013muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"43","author":[{"given":"Manuel R. De Jesus","family":"Escano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily A.","family":"Vertosick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeta","family":"D\u2019Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Benfante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew T.","family":"Lenis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Reisz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Gaffney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvin","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy F.","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Machele","family":"Donat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry W.","family":"Herr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Dalbagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean","family":"Bajorin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy","family":"Sarungbam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikmat","family":"Al-Ahmadie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard H.","family":"Bochner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D.","family":"Sjoberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene J.","family":"Pietzak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.04.006_bib0001","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.urology.2013.10.030","article-title":"Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop","volume":"83","author":"Jarow","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0002","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0003","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/UPJ.0000000000000481","article-title":"US clinical practice patterns of intravesical chemotherapy for Bacillus Calmette-Guerin-unresponsive and Bacillus Calmette-Guerin-exposed nonmuscle-invasive bladder cancer","volume":"11","author":"Abou Chakra","year":"2024","journal-title":"Urol Pract"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0004","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3233\/BLC-170095","article-title":"Single arm phase I\/II study of everolimus and intravesical gemcitabine in patients with primary or secondary carcinoma in situ of the bladder who failed Bacillus Calmette Guerin (NCT01259063)","volume":"3","author":"Dalbagni","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0005","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.juro.2013.04.120","article-title":"Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guerin treatment failure","volume":"190","author":"Sternberg","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0006","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in Bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0007","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0008","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0009","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.euf.2021.09.005","article-title":"Sequential gemcitabine plus docetaxel is the standard second-line intravesical therapy for Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer: con","volume":"8","author":"Grobet-Jeandin","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0010","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.euf.2021.07.018","article-title":"Sequential gemcitabine plus docetaxel is the standard second-line intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer: pro","volume":"8","author":"Roumiguie","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0011","first-page":"2629","article-title":"Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs","volume":"5","author":"Cozzi","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0012","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.juro.2013.04.031","article-title":"SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin","volume":"190","author":"Skinner","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0013","unstructured":"Food and Drug Administration. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry. 2018.https:\/\/www.federalregister.gov\/documents\/2018\/02\/13\/2018-02871\/bacillus-calmette-gurin-unresponsive-nonmuscle-invasive-bladder-cancer-developing-drugs-and."},{"key":"10.1016\/j.urolonc.2025.04.006_bib0014","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0016","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 Superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0017","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0018","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0019","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0022-5347(05)67022-X","article-title":"Ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials","volume":"164","author":"Van Der Meijden","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0020","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.eururo.2009.03.052","article-title":"Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications","volume":"57","author":"May","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0021","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00345-014-1383-5","article-title":"Mixed low- and high-grade non-muscle-invasive bladder cancer: a histological subtype with favorable outcome","volume":"33","author":"Schubert","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0022","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0023","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-160084","article-title":"Efficacy of mycobacterium phlei cell wall-nucleic acid complex (MCNA) in BCG-unresponsive patients","volume":"3","author":"Li","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0024","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.juro.2014.09.109","article-title":"Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guerin","volume":"193","author":"Morales","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0030","article-title":"Assessment of outcomes associated with the use of newly approved oncology drugs in Medicare beneficiaries","volume":"4","author":"Green","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0026","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41585-019-0220-4","article-title":"Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer","volume":"16","author":"Joice","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0027","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.eururo.2022.08.003","article-title":"Adjuvant intravesical chemohyperthermia versus passive chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer (HIVEC-II): a phase 2, open-label, randomised controlled trial","volume":"83","author":"Tan","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0028","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.euo.2022.10.008","article-title":"Hyperthermic mitomycin C in intermediate-risk non-muscle-invasive bladder cancer: results of the HIVEC-1 trial","volume":"6","author":"Angulo","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0029","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.eururo.2014.10.040","article-title":"Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review","volume":"67","author":"Casey","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0030","article-title":"Emerging roles of urine-based tumor DNA analysis in bladder cancer management","volume":"4","author":"Chaudhuri","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.urolonc.2025.04.006_bib0031","article-title":"Development and validation of an artificial intelligence-based model for detecting urothelial carcinoma using urine cytology images: a multicentre, diagnostic study with prospective validation","volume":"71","author":"Wu","year":"2024","journal-title":"EClinicalMedicine"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925001346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925001346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:32:53Z","timestamp":1762363973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925001346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1078143925001346"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.04.006","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re-analysis of intravesical gemcitabine in the era of Bacillus Calmette-Gu\u00e9rin (BCG)-unresponsive non\u2013muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}